[2]
Gerhard-Herman MD,Gornik HL,Barrett C,Barshes NR,Corriere MA,Drachman DE,Fleisher LA,Fowkes FGR,Hamburg NM,Kinlay S,Lookstein R,Misra S,Mureebe L,Olin JW,Patel RAG,Regensteiner JG,Schanzer A,Shishehbor MH,Stewart KJ,Treat-Jacobson D,Walsh ME,Halperin JL,Levine GN,Al-Khatib SM,Birtcher KK,Bozkurt B,Brindis RG,Cigarroa JE,Curtis LH,Fleisher LA,Gentile F,Gidding S,Hlatky MA,Ikonomidis J,Joglar J,Pressler SJ,Wijeysundera DN, 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vascular medicine (London, England). 2017 Jun; [PubMed PMID: 28494710]
[3]
Niu PP,Guo ZN,Jin H,Xing YQ,Yang Y, Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ open. 2016 Mar 17; [PubMed PMID: 26988347]
[4]
Ahmad F,Degerman E,Manganiello VC, Cyclic nucleotide phosphodiesterase 3 signaling complexes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2012 Sep; [PubMed PMID: 22692928]
[6]
Abdel-Latif AA, Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. Experimental biology and medicine (Maywood, N.J.). 2001 Mar; [PubMed PMID: 11361033]
[7]
Kishi H,Ye LH,Nakamura A,Okagaki T,Iwata A,Tanaka T,Kohama K, Structure and function of smooth muscle myosin light chain kinase. Advances in experimental medicine and biology. 1998; [PubMed PMID: 9889833]
[8]
Elam MB,Heckman J,Crouse JR,Hunninghake DB,Herd JA,Davidson M,Gordon IL,Bortey EB,Forbes WP, Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, thrombosis, and vascular biology. 1998 Dec; [PubMed PMID: 9848888]
[9]
Björnsson OG,Sparks JD,Sparks CE,Gibbons GF, Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases. European journal of clinical investigation. 1994 Feb; [PubMed PMID: 8206083]
[10]
Motoyashiki T,Morita T,Ueki H, Involvement of the rapid increase in cAMP content in the vanadate-stimulated release of lipoprotein lipase activity from rat fat pads. Biological [PubMed PMID: 8951155]
[11]
Chapman TM,Goa KL, Cilostazol: a review of its use in intermittent claudication. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2003; [PubMed PMID: 14727939]
[12]
Bramer SL,Forbes WP, Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clinical pharmacokinetics. 1999; [PubMed PMID: 10702883]
[13]
Reilly MP,Mohler ER 3rd, Cilostazol: treatment of intermittent claudication. The Annals of pharmacotherapy. 2001 Jan; [PubMed PMID: 11197586]
[14]
Woo SK,Kang WK,Kwon KI, Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clinical pharmacology and therapeutics. 2002 Apr; [PubMed PMID: 11956507]
[15]
Rogers KC,Oliphant CS,Finks SW, Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015 Mar; [PubMed PMID: 25758742]
[16]
Packer M,Carver JR,Rodeheffer RJ,Ivanhoe RJ,DiBianco R,Zeldis SM,Hendrix GH,Bommer WJ,Elkayam U,Kukin ML, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. The New England journal of medicine. 1991 Nov 21; [PubMed PMID: 1944425]
[17]
Bangalore S,Singh A,Toklu B,DiNicolantonio JJ,Croce K,Feit F,Bhatt DL, Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open heart. 2014; [PubMed PMID: 25332804]
[18]
Umazume T,Funabashi N,Inoue T,Nishi T,Shimizu T,Jo K,Ishikawa T,Nakamura Y,Miyazaki A,Kobayashi Y, Adverse effects of cilostazol on left ventricular function in a patient with a sigmoid shaped interventricular septum. International journal of cardiology. 2013 May 25; [PubMed PMID: 22995418]
[19]
Anderson JL,Halperin JL,Albert NM,Bozkurt B,Brindis RG,Curtis LH,DeMets D,Guyton RA,Hochman JS,Kovacs RJ,Ohman EM,Pressler SJ,Sellke FW,Shen WK, Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Apr 2; [PubMed PMID: 23457117]